GET THE APP

Bullous pemphigoid in a psoriatic patient after adalimumab therapy: Remission with ustekinumab | Abstract
Journal of Perioperative Medicine

Journal of Perioperative Medicine
Open Access

ISSN: 2684-1290

+44 20 3868 9735

Abstract

Bullous pemphigoid in a psoriatic patient after adalimumab therapy: Remission with ustekinumab

A Papadopoulou

Bullous pemphigoid (BP) is an acquired autoimmune blistering disease affecting especially the elderly. Among drugs implicated in BP pathogenesis, anti TNFa agents have been reported as inducing agents. Ustekinumab is a monoclonal antibody that targets the IL-12/23 receptor and is approved for treating moderate to severe psoriasis. Coexistence of BP and psoriasis represents a therapeutic challenge. We report a 52 year old male patient with psoriasis who developed BP after treated with adalimumab. Long term remission of both cutaneous diseases was achieved after administration of ustekinumab. In our knowledge, this is the second case of completely resolution of BP and psoriasis with monoclonal IL-12/23 agent.

Published Date: 2020-09-18; Received Date: 2020-06-10